124 related articles for article (PubMed ID: 15690710)
1. [Polycystic ovary syndrome associated with remarkable hyperprolactinemia--case report].
Owecki M; Sowiński J
Pol Merkur Lekarski; 2004 Oct; 17(100):385-7. PubMed ID: 15690710
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
[TBL] [Abstract][Full Text] [Related]
3. Hyperprolactinemia in children during the peripubertal period--personal observations.
Noczyńska A; Wasikowa R
J Pediatr Endocrinol Metab; 2004 Oct; 17(10):1399-404. PubMed ID: 15526718
[TBL] [Abstract][Full Text] [Related]
4. Menstrual abnormalities in a woman with ACTH-dependent pituitary macroadenoma mimicking polycystic ovary syndrome.
Liao CC; Lin SY; Lin HW; Chen KH; Chang LH; Chen ST; Wang J
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):176-9. PubMed ID: 17197364
[TBL] [Abstract][Full Text] [Related]
5. Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome.
Escobar-Morreale HF
Fertil Steril; 2004 Dec; 82(6):1697-9. PubMed ID: 15589886
[TBL] [Abstract][Full Text] [Related]
6. [Relation between hyperprolactinemia and polycystic ovary syndrome].
Hámori M; Szendei G; Kovács I; Somos P
Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
8. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
9. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
10. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
Robin G; Catteau-Jonard S; Young J; Dewailly D
Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
[TBL] [Abstract][Full Text] [Related]
11. Prolactin secretion in polycystic ovary syndrome (PCOS).
Szosland K; Pawlowicz P; Lewiński A
Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
[TBL] [Abstract][Full Text] [Related]
12. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
13. Adolescent menstrual irregularity.
Mansfield MJ; Emans SJ
J Reprod Med; 1984 Jun; 29(6):399-410. PubMed ID: 6379175
[TBL] [Abstract][Full Text] [Related]
14. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
[TBL] [Abstract][Full Text] [Related]
15. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
16. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
17. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
19. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management.
Davoudi Z; Araghi F; Vahedi M; Mokhtari N; Gheisari M
Acta Biomed; 2021 Nov; 92(5):e2021291. PubMed ID: 34738596
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
